RecruitingPhase 1NCT05981703

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Sponsor

BeOne Medicines

Enrollment

217 participants

Start Date

Sep 21, 2023

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor Solid Tumor

Summary

This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BGB-26808, a drug called Chemotherapy, and others for people with advanced solid tumor and solid tumor. The study is currently recruiting participants at 28 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBGB-26808

Planned doses administered orally as a tablet daily.

DRUGTislelizumab

Planned doses administered by intravenous infusion.

DRUGChemotherapy

Administered in accordance with relevant local guidelines and/or prescribing information.

Locations(28)

City of Hope National Medical Center

Duarte, California, United States

University of Southern California Norris Comprehensive

Los Angeles, California, United States

Yale University Yale Cancer Center

New Haven, Connecticut, United States

Sylvester Cancer Center, University of Miami

Miami, Florida, United States

University of Michigan Health System

Ann Arbor, Michigan, United States

John Theurer Cancer Center Hackensack University Medical Center

Hackensack, New Jersey, United States

Icahn School of Medicine At Mount Sinai

New York, New York, United States

Providence Portland Medical Center

Portland, Oregon, United States

The University of Texas Md Anderson Cancer Center

Houston, Texas, United States

Southside Cancer Care

Miranda, New South Wales, Australia

Macquarie University

North Ryde, New South Wales, Australia

Icon Cancer Centre Kurralta Park

Kurralta Park, South Australia, Australia

Linear Clinical Research

Nedlands, Western Australia, Australia

The First Affiliated Hospital of Anhui Medical Universitygaoxin Branch

Hefei, Anhui, China

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

Hubei Cancer Hospital

Wuhan, Hubei, China

Tongji Hospital,Tongji Medical College of Hustsino French New City Branch

Wuhan, Hubei, China

The First Hospital of China Medical University Hunnan Branch

Shenyang, Liaoning, China

Jining No1 Peoples Hospital West Branch

Jining, Shandong, China

Yantai Yuhuangding Hospital

Yantai, Shandong, China

Shanghai East Hospital Branch Hospital

Shanghai, Shanghai Municipality, China

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital

Chengdu, Sichuan, China

Hangzhou First Peoples Hospital

Hangzhou, Zhejiang, China

Taizhou Hospital of Zhejiang Province (East)

Taizhou, Zhejiang, China

Auckland City Hospital

Auckland, New Zealand

Harbour Cancer and Wellness

Auckland, New Zealand

Health New Zealand Te Whatu Ora Lakes Rotorua Hospital

Rotorua, New Zealand

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05981703

Related Trials

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

NCT0485565622 locations

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

NCT074893781 location

Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies

NCT0709829910 locations

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

NCT0493961041 locations

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

NCT057658518 locations